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The International Regulation of Genetically Modified
Organisms: Importing Caution Into the
U.S. Food Supply
DEBRA M. STRAUSS*
I. INTRODUCTION
Biotechnology is big business.1 As such, the use of biotechnology to engineer plants,
and the regulation of the resulting food crops, involves economic and trade issues, as
well as science and health issues.2
Through modern biotechnology, selected individual genes are transferred from one
organism into another, sometimes between nonrelated species, using recombinant DNA
(rDNA) methods.3 The genetically modified organisms (GMOs) that are created as GM
plants then produce GM foods.4 The first GM crop—the GM tomato—was sold in the
market in 1994,5 and genetically modified products have been commercially available
in the United States since 1995.6 Genes derived from a bacterium in the soil, Bacillus
thuringiensis (Bt), have been inserted into crops to promote resistance to certain insects,
producing Bt-corn, Bt-cotton, Bt-potato, Bt-rice, and Bt-tomato. Glyphosate-tolerant
soybeans (e.g., Roundup Ready® by Monsanto) contain a gene that protects them from
the herbicide glyphosate so that the fields can be sprayed with the herbicide, thus killing
the weeds while leaving the soybeans standing. Herbicide-resistant varieties of canola,
cotton, corn, radicchio, rice, and sugar beet also are on the market. The United States
has approved virus-resistant varieties of papaya, potato, and squash, along with tomato
*
Debra Strauss is an Assistant Professor of Business Law, Fairfield University, Charles F. Dolan School
of Business, Fairfield, Conn. She received her B.A. from Cornell University and her J.D. from Yale Law
School. Professor Strauss, a former Food and Drug Law Institute Scholar, currently teaches international
business law.
1
Biotechnology is one of the fastest-growing sectors of the U.S. economy. The interests of global
business are substantial as well—71% of all agrobiotechology patents are owned by the top five companies
in the area: Pharmacia (now owned by Pfizer Inc.) (21%, 287 patents), DuPont (20%, 279 patents), Syngenta
(13%, 173 patents), Dow (11%, 157 patents), and Aventis (6%, 77 patents). Tzu-Ming Pan, Current Status
and Detection of Genetically Modified Organism, 10 J. FOOD & DRUG ANALYSIS 229, 230 (2002) (citing ETC
Group, Globalization Inc. Communique #71 (2001)).
2
For background on this issue, including additional statistics, see Debra M. Strauss, Genetically Modified Organisms in Food: A Model of Labeling and Monitoring With Positive Implications for International
Trade, 40 INT’L LAW. 95 (2006). Some of the points that will be discussed here expand upon points that were
raised in this article.
3
BINAS Online, Facts on GMOs in the EU, http://binas.unido.org/binas/regs.php (last visited Mar.
16, 2006) [hereinafter Facts on GMOs in the EU]; NATIONAL RESEARCH COUNCIL, SAFETY OF GENETICALLY
ENGINEERED FOODS: APPROACHES TO ASSESSING UNINTENDED HEALTH EFFECTS (July 2004) [hereinafter NRC
SAFETY], available at http://www.nap.edu/html/ge_foods/ge-foods-reportbrief.pdf (“Recombinant DNA
methods enable the insertion of a gene or gene sequence in an exact place in the DNA of the new host, thus
producing a targeted result.”).
4
World Health Organization (WHO), Food Safety, 20 Questions on Genetically Modified (GM) Foods,
http://www.who.int/foodsafety/publications/biotech/20questions/en/index.html (last visited May 11, 2006)
[hereinafter WHO, Questions on GM Foods].
5
Pan, supra note 1, at 230 (citing ISAA ANNUAL REPORT 2002).
6
In 1990, FDA approved the first biotechnology food product for the U.S. market—chymosin, a foodprocessing enzyme produced by GM bacteria. Chymosin is the active enzyme in rennet, a milk-clotting agent
used to make cheese. Traditionally, rennet was obtained from calf stomach linings. U.S. FOOD AND DRUG
ADMINISTRATION (FDA), SAFETY ASSURANCE OF FOODS DERIVED BY MODERN BIOTECHNOLOGY IN THE UNITED STATES
(July 1996), available at http://www.cfsan.fda.gov/~lrd/biojap96.html.
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and cantaloupe, which contain a gene that slows the ripening process to allow fruit to
ripen longer on the vine.7
Worldwide, GMOs have grown exponentially; the total area of biotech crops increased
thirty times between 1996 and 2001. As global plantings of biotech crops grew to about
200 million acres in 2004, about two-thirds of the plantings took place in the United
States.8 More than 40% of the corn, more than 50% of the cotton, and more than 80%
of soybean acres planted in the United States have been genetically modified. As a
conservative estimate, at least 70% of food products in U.S. supermarkets—boxed cereals, other grain products, frozen dinners, cooking oils, and more—contain GMOs.9 The
Grocery Manufacturers of America (GMA) estimates that 75% of all processed foods
in the United States contain a GM ingredient, including almost every product with a
corn or soy ingredient and some containing canola or cottonseed oil.10
Yet, obstacles from abroad have closed the international market not only for foods
genetically engineered in the United States, but also for a significant portion of all U.S.
produce.11 This ban has occurred in part because, unlike the European community, the
United States does not segregate, label, or treat GM foods differently from traditional
foods. The divergent approaches to the regulation of GM foods—ranging from premarket approval requirements, bans, and strict monitoring to voluntary guidelines for
the industry—originate from differences in the attitudes towards GM foods between
the United States and the international community.12 In the international community,
heated debates have focused on the public health, safety, and environmental issues
of introduced genes, particularly, allergenicity, antibiotic resistance, gastrointestinal
problems, potential gene flow to other organisms, and destruction of biodiversity.13
Most significant is the way U.S. and foreign regulators have reacted to these concerns,
reflecting conflicting perceptions and views of the potential risks involved with GMOs
and how to manage these risks.
As GMOs become an increasingly dominant part of the U.S. food supply, it is important to explore the basis for these concerns and the disparity in the regulatory responses
to this technology. Part II of this article analyzes the science of GMOs, particularly the
potential risks and level of uncertainty. Part III examines the rigorous regulatory scheme
set forth by the international community in response to this scientific uncertainty. Part IV
discusses the relatively unrestrictive approach of the United States towards GM foods,
which contrasts markedly with the view overseas. Part V establishes the foundation for
a new regulatory approach in the United States, while considering the increased costs,
based on increased consumer demand and the need for transparency to make choice
possible. Accordingly, this article sets forth an expanded model for the United States
7
FDA, List of Completed Consultations on Bioengineered Foods (Nov. 2005), http://www.cfsan.
fda.gov//~lrd/biocon.html; see also Monsanto, Products and Solutions, Setting the Standard in the Field,
http://www.monsanto.com/monsanto/layout/products/default.asp (last visited May 11, 2006) (bringing to
market second generation of biotechnological traits, e.g., soybeans that can reduce the amount of trans fat
in processed foods).
8
Associated Press, Americans Clueless About Gene-Altered Foods (Mar. 24, 2005) [hereinafter
Americans Clueless], available at http://pewagbiotech.org/newsroom/summaries/display.php3?NewsID=857
(statement of Stephanie Childs, Grocery Manufacturers of America).
9
Id.; see also Roger N. Beachy, Facing Fear of Biotechnology, 285 SCI. 335 (1999), available at www.
biotech-info.net/facing_fear.html.
10
Americans Clueless, supra note 8.
11
For a discussion of the EU moratorium and the efforts of the United States to challenge the ban in
the WTO, see infra notes 104-06, 161-63 and accompanying text.
12
Pan, supra note 1, at 232; see also Farid E. Ahmed, Detection of Genetically Modified Organisms
in Food, 20 TRENDS BIOTECHNOLOGY 215 (2002).
13
Ahmed, supra note 12, at 215.
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of mandatory labeling and pre- and postmarket monitoring, including the development
of more sophisticated testing and tracking of GM food components. Part VI concludes
that, in light of scientific uncertainty and risks of unintended adverse effects, a more
cautious approach akin to the international scheme should be adopted in the United
States. By fulfilling its responsibility to respond appropriately to the concerns of its
citizens, the U.S. government actually would be aiding the viability of GM development
in the long run—thereby facilitating industry efforts to gain acceptance, building consumer confidence in the food supply, and opening additional markets to their products.
More stringent monitoring and labeling of GMOs in the food supply is critical for the
biotechnology and food industries, as well as consumers, particularly in the area of
international trade. Only by implementing standards of accountability and regulations
comparable to the international community can the United States truly achieve its goal
of opening the global marketplace to U.S. agricultural products.

II. THE SCIENCE: RISKS AND UNCERTAINTY
Any fair examination of biotechnology in agriculture should acknowledge the potential benefits of genetically engineered foods. A study commissioned by the World
Health Organization (WHO) cited several benefits of this food technology, including the
potential for increased agricultural productivity and improved nutritional values, along
with “reduced agricultural chemical usage and enhanced farm income, and improved
crop sustainability and food security, particularly in developing countries.”14 Proponents
point to the goals of reducing hunger by increasing food productivity; conserving the
environment by reducing pesticide and herbicide use; enhancing nutritional content;
and improving food quality.15 Many would argue, however, that the opportunity to direct
biotechnology to meet these lofty goals has been squandered (e.g., on the development
of herbicide resistant plants engineered to survive the spraying of these pesticides or
“terminator” seeds that cannot reproduce, forcing these impoverished developing countries to buy additional seeds from the manufacturer). Moreover, these largely unrealized
benefits in fact may be outweighed by the potential of new dangers to human health
and the environment.
The WHO study identified several risks presented by GMOs and GM foods for human health as part of its safety assessment, including: direct health effects (toxicity),
tendencies to provoke allergic reaction (allergenicity), specific components with toxic
properties, the stability of the inserted gene, nutritional impact, and any unintended effects that could result from genetic modification.16 Of particular concern is gene transfer,
whereby genes from bioengineered foods could transfer to bacteria in the gastrointestinal tract or to cells of the body and cause negative health effects.17 For example, if
the antibiotic-resistant marker genes that typically are inserted with GM material to
facilitate identification of GM cells were transferred, a person could become resistant
14

WORLD HEALTH ORGANIZATION (WHO), MODERN FOOD BIOTECHNOLOGY, HUMAN HEALTH AND DEVELOPEVIDENCE-BASED STUDY, at iii (June 24, 2005) [hereinafter WHO STUDY], available at http://www.
who.int/foodsafety/publications/biotech/biotech_en.pdf; see also Fred Gould & Michael B. Cohen, Sustainable Use of Genetically Modified Crops in Developing Countries, in AGRICULTURAL BIOTECHNOLOGY AND THE
POOR: CONFERENCE PAPERS 139 (Oct. 1999), available at http://www.cgiar.org/biotech/rep0100/Gould.pdf
(discussing the potential of biotechnology crops for increasing yield in developing countries, but recognizing
the need for long-term food security and decreased environmental risks).
15
Pan, supra note 1, at 230.
16
See WHO STUDY, supra note 14.
17
WHO, Questions on GM Foods, supra note 4.
MENT: AN
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to antibiotic medicines. Consequently, WHO cautions against using antibiotic-resistant
genes in the GM process.18
In addition to human health risks, GM foods pose potential risks for the environment,
named in the WHO study as: “unintended effects on non-target organisms, ecosystems,
and biodiversity.”19 The Bt bacterium used to produce insect-resistant GM crops may
cause harmful effects on beneficial insects or development of resistant insects.20 Another
concern is the spread of transgenes in the natural environment; the WHO study reports that
such outcrossing occurred in “fields of commercially grown GM plants, including oilseed
rape and sugar beet, and has been demonstrated in experimental releases for a number of
crops, including rice and maize.”21 Ultimately, there is a fear that through cross-pollination
GMOs may become the dominant species and irreversibly alter the ecosystem.22
Despite these identified risks, GM crops continue to be developed and GM food
continues to be consumed by a public largely unaware of the potential hazards.23 Few
long-term scientific studies have been completed.24 Arpad Pusztai, a scientist who has
reviewed the research and advocates additional studies on the human health effects of
GM food, attributes the lack of data to a number of reasons, including the fact that it is
“more difficult to evaluate the safety of crop-derived foods than individual chemical,
drug, or food additives. Crop foods are more complex and their composition varies
according to differences in growth and agronomic conditions.”25 In the few animal
studies that have been done, some of the initial findings have been troubling, including the following results: when fed GM tomatoes, some rats died within a few weeks;
after eating GM soybeans, rats had inadequate weight gain; rats that had ingested GM
corn had a decreased digestive ability; toxins were present in mice that had eaten GM
potatoes; the toxin level of GM cotton was deemed “unpredictable”; and GM soybeans
contained increased allergens.26 These studies have prompted some scientists to recommend “more and better testing methods before making GM foods available for human
consumption.”27
18
Id. (FAO/WHO expert panel recommendations). At least one study found that the antibiotic-resistant
marker from a burger containing GM soy found its way into human gut bacteria; “the bacteria had taken
up the herbicide-resistant gene from the GM food at a very low level.” Study Shows Disadvantages of GM
Foods to Human Health, GUARDIAN, Aug. 2002, available at http://www.non-gmosource.com/disadvantages_
GM_food_health.php; see also THE ROYAL SOCIETY, GENETICALLY MODIFIED PLANTS FOR FOOD USE AND HUMAN
HEALTH—AN UPDATE (Feb. 2002), available at http://www.royalsoc.co.uk/displaypagedoc.asp?id=11319.
19
WHO STUDY, supra note 14.
20
Id.
21
Id.
22
See, e.g., Pan, supra note 1, at 231; Nathan Batalion, 50 Harmful Effects of Genetically Modified
Food (2000), http://www.cqs.com/50harm.htm.
23
Arpad Pusztai, Genetically Modified Foods: Are They a Risk to Human/Animal Health? (June 2001),
http://www.actionbioscience.org/biotech/pusztai.html (noting that safety test technology is inadequate to
assess potential harm, that GM foods can carry unpredictable toxins, and that GMOs may increase the risk
of allergenic reactions).
24
DONNA U. VOGT & MICKEY PARISH, FOOD BIOTECHNOLOGY IN THE UNITED STATES: SCIENCE, REGULATION,
AND ISSUES (CRS Rep. RL30198) (Jan. 19, 2001) [hereinafter CRS REPORT], available at http://ncseonline.
org/NLE/CRSreports/science/st-41.pdf.
25
Id. (citing Jose L. Domingo, Health Risks of Genetically Modified Foods: Many Opinions But Few
Data, 288 SCI. 1748 (2000)).
26
Pusztai, supra note 23; see also Batalion, supra note 22. But see ROYAL SOCIETY UPDATE, supra note
18 (“studies, on the results of feeding GM sweet peppers and GM tomatoes to rats, and GM soya to mice
and rats, have [found] no adverse effects”) (citing Michael Gasson & Derek Burke, Scientific Perspectives on
Regulating the Safety of Genetically Modified Foods, 2 NATURE REVIEWS GENETICS 207, 217 (2001)).
27
Pusztai, supra note 23. For a related examination of the health issues, see, for example, MARIE-CLAIRE
CORDONIER SEGGER & ASHFAQ KHALFAN, SUSTAINABLE DEVELOPMENT LAW: PRINCIPLES, PRACTICES, AND PROSPECTS
(Oxford Univ. Press 2004); see also Craig Segall, Book Review, 24 STAN. ENVTL. L.J. 341 (2005) (reviewing
MARIE-CLAIRE CORDONIER SEGGER & ASHFAQ KHALFAN, SUSTAINABLE DEVELOPMENT LAW: PRINCIPLES, PRACTICES,
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Some of the potential hazards of bioengineered foods already have been revealed in
several cases. One of the first GM products brought to market—a genetically altered
version of the dietary supplement L-tryptophan—illustrated the risks of toxicity to
humans. When Showa Denko, Japan’s third largest chemical company, introduced the
GM version of L-tryptophan into the United States in the late 1980s, at least 1500 people
were permanently disabled and thirty-seven died from neurological problems connected
with eosinophilia-myalgia syndrome. It took months before the doctors who treated the
syndrome noticed the link to patients taking tryptophan produced by Showa Denko,
which contained a toxic contaminant determined to be a byproduct of the increased
tryptophan production of the genetically engineered bacteria.28 If the supplement had
been labeled as genetically engineered, the source of the problem might have been
discovered sooner and the product removed from the market more promptly.29
Allergies also are a significant concern with GM food, especially if these ingredients
are not labeled, but “there are no reliable ways to test GM foods for allergies.”30 When
Pioneer Hi-Bred spliced Brazil nut genes into a soybean to improve its protein content,
the altered soybean provoked severe allergic attacks in eight individuals sensitive to
Brazil nuts but not soybeans.31 Fortunately, due to unique circumstances, including
awareness that this type of nut could be a serious allergen and serum samples from
persons allergic to the donor species were available for testing, the testing was done
premarket and the company withdrew the product.32 This case illustrates the dangers of
the absence of labeling; without a label alerting consumers that a soybean could contain
genes from a highly allergic nut, even individuals aware of their severe allergies would
have no warning.33
There have been suggestions that certain ingredients in GM foods may even be linked
to cancer.34 In 1994, the Food and Drug Administration (FDA) approved Monsanto’s
recombinant Bovine Growth Hormone (rBGH), also known as, bovine somatotropin
PROSPECTS (Oxford Univ. Press 2004)); Heather N. Ellison, Genetically Modified Organisms: Does the
Current Regulatory System Compromise Consumer Health?, 10 PENN ST. ENVTL. L. REV. 345 (2002); Julie
Teel, Rapporteur’s Summary of the Deliberative Forum: Have NGO’s Distorted or Illuminated the Benefits
and Hazards of Genetically Modified Organisms?, 13 COLO. J. INT’L ENVTL. L. & POL’Y 137 (2002); Ellen
Messer, Food Systems and Dietary Perspective: Are Genetically Modified Organisms the Best Way to Ensure
Nutritionally Adequate Food?, 9 IND. J. GLOBAL LEGAL STUD. 65, 69-70 (2001).
28
Arthur N. Mayeno & Gerald J. Gleich, Eosinophilia Myalgia Syndrome and Tryptophan Production:
A Cautionary Tale, 12 TRENDS BIOTECHNOLOGY 346 (1994).
29
Batalion, supra note 22 (citing Arthur N. Mayeno & Gerald J. Gleich, Eosinophilia Myalgia Syndrome
and Tryptophan Production: A Cautionary Tale, 12 TRENDS BIOTECHNOLOGY. 346 (1994)); see also Jean Halloran & Michael Hansen, Why We Need Labeling of Genetically Engineered Food, 18 SYNTHESIS/REGENERATION
(1999), available at http://www.consumersunion.org/food/whywenny798.htm (detailing potential allergic,
toxic, and antibiotic resistance effects of genetically altered food).
30
Pusztai, supra note 23.
31
Julie A. Nordlee et al., Identification of a Brazil Nut Allergen in Transgenic Soybeans, 334 NEW
ENG. J. MED. 688 (1996).
32
Marion Nestle, Allergies to Transgenic Foods: Questions of Policy, 334 NEW ENG. J. MED. 726
(1996).
33
“About 25% of Americans have adverse reactions to foods. 8% of children and 2% of adults have
food allergies as tested by blood immunoglobins.” Some “individuals … are so allergic to [the Brazil] nut,
they go into apoplectic shock (similar to a severe bee sting reaction), which can cause death.” Batalion, supra
note 22. Because the typical focus is on “food with genes transferred from the 8 to 10 most commonly allergenic foods, public-interest groups have cautioned that existing rules inadequately protect people against
lesser-known transgenic allergens to which they might be sensitive.” Nestle, supra note 32.
34
Several GM food products approved for use in the United States “involve herbicides that are commonly known carcinogens—bromoxynil used on transgenic cotton and Monsanto’s Roundup or glufonsinate
used on GM soybeans, corn, and canola.” In addition, “unexpected gene fragments have shown up in GM
soy crops”—and research has shown that “foreign DNA fragments that are not fully digested in the human
stomach and intestines” enhance a number of autoimmune diseases. Batalion, supra note 22.
AND
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(BST), a genetically produced growth hormone, for injection into dairy cows, disregarding warnings from scientists of the resulting increase of IGF-1, a potent chemical
hormone with evidence indicating 400% to 500% higher risks of human breast, prostrate,
and colon cancer.35 Studies show that rBGH increases the levels in milk of insulin-like
growth factor (IGF-1), a powerful stimulator and regulator of cell-growth and division
in cows and humans—particularly children—that has been linked to cancer.36 Despite
these concerns, FDA has repeatedly defended its approval of rBGH, publishing a
review of the data and concluding that rBGH “presents no increased health risk.”37 In
May 1994, FDA’s Food Advisory Committee and Veterinary Medicine Advisory Committee discussed whether foods should be labeled as containing supplemental rBGH;
the committee report stated that “deliberations indicate that any method for instituting
labeling for food from BST-supplemented cows would have to resolve many difficult
scientific and policy questions.”38 To date, no such labeling of milk products is required
by FDA.39 Furthermore, the courts have deferred to the agency position on the nonlabeling of rBGH.40
The potential impact of GMOs on ecosystems was dramatically exhibited by a study
of biotech corn and monarch butterflies at Cornell University.41 When scientists applied
pollen from Bt-corn to milkweed, a crop that the butterflies eat and that grows near cornfields, forty-four percent of the monarch larvae died.42 None of the monarch larvae in the
study that were fed corn pollen from nonengineered plants died.43 Some scientists caution
that additional research needs to be done, for example, in the monarch butterfly’s natural
habitat, before concluding that widespread harm to the ecosystem will result.44 Still, the
35

Id.
Press Release, Cancer Prevention Coalition, New Study Warns of Breast and Colon Cancer Risks from
rBGH Milk (Jan. 23, 1996), available at http://www.preventcancer.com/press/conference/jan23_96.htm; see
also, Samuel Epstein, Potential Public Health Hazards of Biosynthetic Milk Hormones, 20 INT’L J. HEALTH
SERVS. 73 (1990); National Institutes of Health, Technology Assessment Conference Statement on Bovine
Somatotropin, 265 JAMA 1423 (1991).
37
CRS REPORT, supra note 24. On December 15, 1998, the nonprofit organization Center for Food
Safety petitioned FDA to withdraw approval of rBGH due to possible health effects not addressed by the
agency. As of January 2001, this issue was pending within FDA. Critics continue to question the data upon
which FDA founded its reports and the agency’s close ties with Monsanto. See, e.g., David I. Aboulafia,
Pushing rBST: How the Law and the Political Process Were Used to Sell Recombinant Bovine Somatotropin
to America, 15 PACE ENVTL. L. REV. 603 (1998).
38
Id.
39
Id. Moreover, FDA rejected the request by some companies to label their milk products as “BST-free,”
determining that because BST (BGH) is a normal constituent of milk, such labeling would be misleading.
40
In Stauber v. Shalala, 895 F. Supp. 1178, 1193 (W.D. Wis. 1995), the court deferred to FDA’s finding
that there was no difference between dairy products from rBGH or nontreated cows. Thus, the court upheld
FDA’s determination that it would not require labeling disclosing that dairy products came from rBGH-treated
cows. When the state of Vermont sought to require mandatory disclosure of rBGH use in milk production,
the U.S. Court of Appeals for the Second Circuit struck down the Vermont law on grounds that “consumer
curiosity” was not “substantial” enough to justify the intrusion on commercial free speech under the First
Amendment. Int’l Dairy Foods Ass’n v. Amestoy, 92 F.3d 67, 74 (2d Cir. 1996). See Emily Marden, Recombinant Bovine Growth Hormone and the Courts: In Search of Justice, 46 DRAKE L. REV. 617 (1998).
41
Arjun Makhijani, Ecology & Genetics: An Essay on the Nature of Life and the Problem of Genetic
Engineering, ch. 5 (Apex Press 2001). See John E. Losey, Linda S. Rayor & Maureen E. Carter, Transgenic
Pollen Harms Monarch Larvae, 399 NATURE 214 (1999), available at http://www.biotech-info.net/transpollen.html.
42
Id.
43
Id.; see also Danielle Knight, Environment: New Report Fuels Debate on GMO’s, ENVTL. BULL.,
June 4, 2001, at 1, 2.
44
For example, researchers point out that most milkweed on which monarch larvae feed does not grow
close enough to cornfields to be exposed to significant amounts of corn pollen. Further, the timing is important
and the monarch larvae would have to be emerging and feeding at the same time the corn is pollinating; they
would have other food choices as well. Additional research is underway to determine whether Bt-corn poses
36
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fact that ingesting Bt-corn had this effect is troubling. A report from the nongovernmental Institute for Energy and Environmental Research (IEER) concluded from this study,
“Whether Bt corn will actually have severe impacts on monarch butterfly populations is
less important to the overall issue than the fact of the unanticipated toxicity of Bt corn
pollen. It should serve as a huge warning signal of the possibility of ecosystem disruption
due to the widespread introduction of engineered species.”45
Outcrossing also could have a direct impact on human health and food safety, as
was demonstrated when traces of a maize type that was only approved for feed use
appeared in maize products for human consumption in the United States.46 StarLink,
a corn genetically engineered with a [Cry9C] protein to protect crops against certain
insects, was considered suitable only for animal feed because of concerns that it could
cause allergic reactions in humans; but StarLink accidentally entered the food supply,
prompting a large scale recall of about 300 corn products.47 In addition, the cross-contamination had an impact on international trade, causing a drop in Japanese imports
of U.S. corn by 1.3 million metric tons (eight percent in volume terms) in 2001. The
Japanese government now mandates the segregation of unapproved biotechnology food
and feed ingredients from the export channel, allowing a one percent tolerance for the
unintended presence of these components.48
Further concerns about the U.S. food supply come from the latest use of biotechnology in crops to generate the production of drugs. A small biotechnology company,
Ventria Biosciences, plans to insert human genes into rice plants to produce two proteins normally found in breast milk, tears, and saliva, in turn generating “therapeutic
food products to treat stomach disorders.”49 Several other biotechnology companies are
experimenting with drugs grown in plants because using this GM method to produce
drugs in mass quantities of field plantings is less costly than a traditional biotechnology
factory.50 A consulting firm forecasts that the first plant-manufactured drugs will reach
the U.S. market next year and expand into a $2.2 billion-per-year industry by 2011.51
Consumer and environmental advocates, and many farmers (i.e., American Farm
Bureau and National Farmers Union), fear that pollen from GM drug plants could drift
into fields containing food crops and create contaminated hybrids.52 Moreover, a bird
could ingest the bioengineered seeds and deposit them in a field hundreds of miles

a significant danger to the monarch butterfly in the long run. See Novartis, Q & A: Monarch Butterflies and
Bt Corn, Syngenta Cuts (2000), http://www.checkbiotech.org/blocks/dsp_document.cfm?doc_id=83; U.S.
Dep’t of State, Fact Sheet: Monarch Butterflies and Bt Corn: A Review of the Research, 4 ECON. PERSP. (1999),
http://usinfo.state.gov/journals/ites/1099/ijee/bio-monarch.htm.
45
Press Release, Inst. for Energy and Envtl. Research (IEER), Ecological Impacts of Genetically Engineered Plants May Be Severe Harm Possibly Greater Than From Toxic Chemicals (June 4, 2001), available
at http://www.ieer.org/comments/genetics/e&g-prl.html (statement of Arjun Makhijani, President, IEER).
46
WHO, Questions on GM Foods, supra note 4, at Q5.
47
Martin A. Lee, Food Fight: International Protests Mount Against Genetically Engineered Crops, S.F.
BAY GUARDIAN, June 25, 2001, available at http://www.gefoodalert.org/News/news.cfm?News-ID=w2780
(“While acknowledging that nearly a half billion bushels of corn in storage nationwide contain StarLink,
Aventis denies that it poses a health risk to humans.”).
48
James Stamps, Trade in Biotechnology Food Products, INT’L ECON. REV. 5, 13-14 (2002); see also
StarLink Information Center, StarLink History, StarLink—What Happened?, http://www.starlinkcorn.com/
History/What%20Happened.htm (last visited May 11, 2006).
49
Arlene Weintraub, What’s So Scary About Rice? Biotech Crops Can Make Drugs—But They Must
Be Kept Out of the Food Chain, BUS. WK., Aug. 1, 2005, at 58.
50
“A traditional biotech factory might cost Ventria … $125 million,” but rice yields “the same output
for $4 million.” Chief Executive Officer Scott Deeter says “he intends to pass the savings to consumers. Id.
51
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away.53 Even others in industry resist the use of biotech crops for drug production;
Anheuser-Busch has waged a battle against this development in Missouri, fearing contamination of the rice plants that are a key ingredient in the company’s beer.54 Margaret
Mellon, Director of the Food and Environment program for the Union of Concerned
Scientists in Washington, D.C. warns that it is “virtually certain this stuff will make it
into food-grade rice.”55
Along with risks to the consumer and the environment come significant potential consequences for international trade. Some $1.3 billion in annual U.S. rice sales to foreign
countries are at stake.56 If drugs migrate into commodity crops, many of these countries,
already wary of biotech crops, would buy their agricultural products elsewhere.57 These
fears are not unfounded, as revealed by an incident in 2002, when a drug-producing
corn made by ProdiGene Inc. began sprouting in soybean fields near its Nebraska and
Iowa sites.58 The U.S. Department of Agriculture (USDA) seized 500,000 bushels of
contaminated soybeans and charged ProdiGene nearly $3 million in fines and disposal
costs. Unless companies and the agencies that regulate them implement safeguards to
prevent these food-safety fears from becoming a reality, this biotech method of drug
production faces an unsteady future.59
The favored method of the U.S. industry has been to make comparisons between
the compositions of GM and non-GM crops. When they are not significantly different
the two are regarded as “substantially equivalent,” and, therefore, the GM food crop
is regarded as safe as its conventional counterpart. As discussed infra, FDA relies on
this substantial equivalence for its view that no additional labeling or animal testing is
required. Substantial equivalence is an unscientific concept, however, that has never
been properly defined or provided with a legal standard for implementation.60 The IEER
report states that:
Tests have not been performed because the regulatory apparatus has bought
into the scientifically unfounded doctrine of “substantial equivalence,” according to which there are assumed to be no differences between genetically
engineered and traditionally bred foods. Today we want to emphasize that this
erroneous notion of “substantial equivalence” at the level of food composition
has its analog at the level of ecological impacts.61
53

Id.
Id. In April 2004, when Anheuser-Busch threatened to boycott all Missouri rice, Ventria shifted its
plans; in June 2005, USDA approved Ventria’s application for plants in North Carolina instead.
55
Id. In an interview, Margaret Mellon of the Union of Concerned Scientists further explained, “when
you’re genetically engineering bioactive molecules—drugs—into crops and they’re growing outdoors, you
must be able to assure those [engineered traits] don’t move to food crops. Otherwise you’re imposing health
and environmental risks.” Online Extra: The Side Effects of Drugged Crops, BUS. WK., July 26, 2005, http://
www.businessweek.com/magazine/content/05_31/b3945092mz018.htm.
56
Weintraub, supra note 49.
57
Id.; Online Extra, supra note 55.
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Weintraub, supra note 49, at 58; see also Spotlight Pharming Reaps Regulatory Changes, AGBIOTECH BUZZ, May 14, 2003, http://pewagbiotech.org/buzz/display.php3?StoryID=101(seeds inadvertently left
behind in former test sites mingled with soybeans that were harvested and stored before the situation was
discovered). Two months earlier, Prodigene had to destroy 155 acres of corn in Iowa because wind-blown
pollen from its drug-producing may have contaminated that too. Take Action, http://www.seedsofdeception.
com/Public/TakeAction/index.cfm (last visited May 17, 2006).
59
Weintraub, supra note 49, at 58-59; see also Carie-Megan Flood, Note, Pollen Drift and Potential
Causes of Action, 28 J. CORP. L. 473, 477-82 (2003) (for legal liability issues associated with these environmental risks).
60
Pusztai, supra note 23 (citing Erik Millstone et al., Beyond Substantial Equivalence, NATURE, OCT.
7, 1999, AT 525).
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IEER Press Release, supra note 45 (statement of Martha R. Herbert, M.D., Ph.D., Pediatric Neurologist, Harvard Medical School).
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It is for this reason that this approach has been rejected in Europe, where the capability
to classify a novel food as being substantially equivalent no longer justifies a lack of
safety assessments.62
According to some of the major regulatory and scientific agencies in the world, GM
crops possess greater dangers than traditional crop breeding methods.63 Scientists have
identified the following as key issues in the environmental assessment of GM crops:
putative invasiveness; vertical or horizontal gene flow; other ecological impacts; effects
on biodiversity; and the impact of the presence of GM material in other products.64 In
view of the complexities of these issues, skilled ecologists and other scientists with
expertise in developing the necessary predictive tools for risk assessment must have a
voice in the public debate.65
A National Academies of Sciences (NAS) National Research Council report clarifies
that “[t]he process of genetic engineering has not been shown to be inherently dangerous,
but rather, evidence to date shows that any technique, including genetic engineering,
carries the potential to result in unintended changes in the composition of the food.”66
Distinguishing between genetic engineering methods67 and nongenetic engineering
methods68 of modifying plants and animals, the report has suggested some possible
mechanisms of unintended change for organisms genetically engineered using rDNA
techniques. For example, chromosomal changes may occur depending on where the
genes were inserted, there may be a loss or gain of whatever function the gene provided,
and spontaneous mutation may occur. As a result, the committee concluded that genetic
engineering presented the greatest likelihood of unintended health effects on its scale in
comparison to nongenetic engineering methods. The National Research Council report
observed that targeted, quantitative analysis—the traditional approach of determining
the presence or amount of compounds produced to assess changes and potential harm to
health—has become much more sophisticated in detecting small molecules, but “more
improvements are still needed.”69
62

See ROYAL SOCIETY UPDATE, supra note 18.
NATIONAL RESEARCH COUNCIL, GENETICALLY MODIFIED PEST-PROTECTED PLANTS: SCIENCE AND REGULATION
(Nat’l Acad. Press 2000); Declan Butler & Tony Reichhardt, Long-Term Effect of GM Crops Serves Up Food
for Thought, NATURE, Apr. 22, 1999, at 651-56; see also John E. Beringer, Releasing Genetically Modified
Organisms: Will Any Harm Outweigh Any Advantage?, 37 J. APPLIED ECOLOGY 207 (2000) (arguing that most
concerns about environmental harm are more relevant to existing crops, that virtually all changes in agricultural
practice have an adverse impact on wildlife, and identifying the problem as how to manage agriculture to
ensure that we maintain or enhance species diversity of wild plants and animals within this context).
64
Anthony J. Conner et al., The Release of Genetically Modified Crops Into the Environment, 33
PLANT J. 19 (2003); see also Stephen Tromans, Promise, Peril, Precaution: The Environmental Regulation
of Genetically Modified Organisms, 9 IND. J. GLOBAL LEGAL STUD. 187 (2001).
65
Alan J. Gray, Ecology and Government Policies: The GM Crop Debate, 41 J. APPLIED ECOLOGY 1
(2004). See generally Margaret Rosso Grossman, Biotechnology, Property Rights and the Environment, 50
AM. J. COMP. L. 215, 217-23 (Supp. 2002) (outlining the risks and benefits associated with GM foods).
66
NRC SAFETY, supra note 3, at 1.
67
Two GE methods (targeted) were described: microbial vectors, a method that takes advantage of a
microbe’s ability to transfer and stably integrate segments of DNA into a plant so that the plant expresses
those traits, and electroporation. In the latter process, plant cells growing in culture are stripped of their
protective walls and electric shock is used to destabilize the cell membrane and allow the introduced DNA
to enter the cell. Id.
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Non-GE methods (nontargeted) include: simple selection, in which plants with desired traits are
selected for continuous propagation; crossing, brushing pollen from one plant onto a sexually compatible
plant to produce a hybrid with genes from both parents; embryo rescue, placing a plant that has naturally
cross-pollinated into a tissue culture environment to enable its full development; and mutagen breeding,
exposing plants or seeds to mutagenic agents (e.g., ionizing radiation) or chemicals to induce random change
in the DNA sequence and assess the new plants for valuable traits. Id.
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Id. at 2.
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The National Research Council report proposed a new framework that could be
used to examine, identify, and evaluate systematically the unintended compositional
changes and health affects of all altered foods, including a safety assessment prior to
commercialization and postmarket surveillance to monitor unanticipated compositional
changes and health effects of genetically engineered foods.70 Most significantly, the
report called for additional research such as developing new tools for detecting health
changes in the population that could result from genetic alteration and for assessing
potential unintended adverse effects.71

III. A CAUTIOUS APPROACH: EUROPEAN UNION
AND INTERNATIONAL LAW
In the face of such significant concerns in the scientific community as to the safety
of GMOs in food, how do regulatory systems proceed? Viewing this level of risk to
be unacceptable, Europeans and the international community take a more cautious approach than the United States. In seeking an explanation for the greater opposition to
food biotechnology in Europe, a study found that different histories of media coverage
and regulation combined with public perceptions that reflected deeper cultural sensitivity not only toward food and novel food technologies but also toward agriculture
and the environment.72 Until recently, consumers in the United States have appeared
to be relatively trusting and uninformed of a technology that in Europe has triggered
extensive public debate, due in part to a history of food and environmental concerns,
lack of transparency, and suspicion towards the government.73
The divergent legal approaches reflect this cultural difference in attitudes through the
level to which scientific uncertainty is factored into risk assessment as part of the regulatory process. The international community gives greater weight to this uncertainty than
does the U.S. government in its treatment of GMOs.74 Because U.S. regulators do not view
biotechnology as posing special risks in and of itself, the regulatory treatment of biotech
products has been limited to fitting them within existing laws addressing known physical
risks of new products.75 In contrast, European regulators have dealt with biotechnology
as “a novel process requiring novel regulatory provisions,” and, as a consequence, have
launched a complex series of European and international initiatives that take into account a
wider range of both known and unknown risks to human health and the environment.76
To provide international consistency in the assessment of GM foods, the Codex Alimentarius Commission—an international standard setting body for food safety jointly
administered by two United Nations agencies, the Food Agriculture Organization (FAO)
and WHO—adopted principles that set a uniform standard for assessing food safety for
foods derived from modern biotechnology.77 The Codex principles set forth a premarket
70

Id.
Id. at 3; see also infra note 212 and accompanying text.
72
George Gaskell et al., Worlds Apart? The Reception of Genetically Modified Foods in Europe and
the U.S., 285 SCI. 384 (1999) (an attitudinal study analyzing public perceptions of biotechnology, together
with press coverage and policy formation).
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Id.; Ahmed, supra note 12, at 215; see also Alexander G. Haslberger, Monitoring and Labeling for
Genetically Modified Products, 287 SCI. 431 (2000).
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Haslberger, supra note 73.
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Gaskell et al., supra note 72.
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77
Codex Alimentarius Commission, Principles for the Risk Analysis of Food Derived from Modern
Biotechnology, CAC/GL 44-2003 (2003), available at http://www.codexalimentarius.net/download/standards/10007/CXG_044e.pdf.
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assessment, implemented on a case-by-case basis, including an evaluation of both direct
effects from the inserted gene and unintended effects that may arise as a consequence
of insertion of the new gene. The safety assessment principles for GM foods require an
investigation of the risks previously identified, namely, toxicity, allergenicity, specific
components having nutritional or toxic properties, the stability of the inserted gene, the
nutritional effects of the specific gene modification, and any unintended effects from
the gene insertion.78 Treaties such as the Agreement on the Application of Sanitary and
Phytosanitary Measures of the World Trade Organization (WTO) embrace the Codex
principles, even though the Codex does not in itself have a binding effect on national
legislation. These principles are further referred to as a standard in cases of trade disputes, including those involving the United States.79
In evaluating this approach to biotechnology and food safety, WHO in its recent
study concluded that the risk assessment guidelines specified by the Codex Commission are “thought to be adequate for the safety assessment of GM foods currently on
the international market.”80 The study determined that GMOs and GM foods should be
assessed on a case-by-case basis for potential risks, while taking into account their characteristics and possible differences in the receiving environments. In particular, relevant
consequences must be investigated for specific crops and strategies for risk management
explored to detect potential risks from outcrossing or contamination from GM crops.
A better understanding of the impact and interaction of food with the immune system
also is required to ascertain how and whether conventional and GM foods cause specific
health and safety problems. WHO supported the Codex Commission in its expectation
that improvements in risk assessment techniques will be included in the premarket approval process launched by many countries under this international guidance.81
As the only international regulatory instrument established to protect biological
diversity from the risks of biotechnology, the Cartagena Protocol on Biosafety of the
Convention on Biological Diversity82 expressly focuses on the potential adverse effects of “living modified organisms” (LMOs) on the environment, while also taking
into account the risks to human health as a secondary consideration.83 The Cartagena
Protocol, an environmental treaty legally binding on its parties, regulates the trade and
transfer of LMOs across borders, including labeling on shipments of GM commodities.84
Through an Advance Informed Agreement (AIA), an exporter must inform potential
78

WHO STUDY, supra note 14, at 12.
The United States has participated in Codex since it was formed in 1962. Id.; Stamps, supra note
48, at 5, 7; see also WHO, Questions on GM Foods, supra note 4.
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WHO STUDY, supra note 14, at 24.
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Cartagena Protocol on Biosafety to the Convention on Biological Diversity (2000), available at
http://www.biodiv.org/biosafety/. The Cartagena Protocol (sometimes referred to as the Biosafety Protocol)
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the fifty instruments of ratification by States or regional economic integration organizations that are Parties
to the UN Convention on Biological Diversity (CBD), which was adopted in Rio de Janeiro in 1992. See
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Protocol. The United States, which had signed the CBD, but had not ratified it, is not among them. For a
list of the status of the ratifying Parties, see The Convention on Biological Diversity, Parties to the Convention on Biological Diversity/Cartagena Protocol on Biosafety, http://www.biodiv.org/world/parties.asp (last
visited May 13, 2006).
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WHO STUDY, supra note 14, at 19.
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Aarti Gupta, Governing Trade in Genetically Modified Organisms: The Cartagena Protocol on
Biosafety, 42 ENV’T 22, 22-23 (2000); see also Lisa A. Tracy, Does a Genetically Modified Rose Still Smell
as Sweet?—Labeling of Genetically Modified Organisms under the Biosafety Protocol, 6 BUFF. ENVTL. L.J.
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participatory countries of all of the information associated with these organisms before
permitting their import. 85
The Cartagena Protocol incorporates a precautionary approach in keeping with the
language of the Rio Declaration on Environment and Development, that “[w]here there
are threats of serious or irreversible damage, lack of full scientific certainty shall not
be used as a reason for postponing cost-effective measures to prevent environmental
degradation.”86 It provides risk scientific detection methods and assessment techniques,
and allows governments to prohibit the import of GM foods because of safety concerns.
Reflected in the Cartagena Protocol’s approach is the recognition that, although the
risks may be unknown,
[l]ack of scientific certainty due to insufficient relevant scientific information
and knowledge regarding the extent of the potential adverse effects of a living modified organism on the conservation and sustainable use of biological
diversity in the Party of import, taking also into account risks to human health,
shall not prevent that Party from taking a decision, as appropriate, with regard
to the import of that living modified organism intended for direct use as food
or feed, or for processing, in order to avoid or minimize such potential adverse
effects.87
Lastly, the Cartagena Protocol establishes a Biosafety Clearing-House “to facilitate the
exchange of scientific, technical, environmental, and legal information, and experience
with, living modified organisms” and to assist countries in the implementation of the
Protocol.88
According to the WHO study, the Cartagena Protocol is only the first step in the international regulation of bioengineered foods.89 Although the Cartagena Protocol is the
key basis for international regulation of LMOs, the Protocol’s scope does not consider
GM foods that do not meet the definition of an LMO. 90 GM foods are within the scope
of the Cartagena Protocol only if they contain LMOs that are capable of transferring or
replicating genetic material. Moreover, the primary focus on biodiversity limits its consideration of human health issues; consequently, “the Protocol alone … is not sufficient
for the international regulation of GM foods.”91 In addition, the WHO study reported the
possibility of implementing postmarket surveillance in the future, but tools to identify
and trace GMOs or products derived from GMOs in the environment and food chain
are needed; detection techniques in a number of countries already facilitate monitoring of GMOs, and attempts to standardize analytical methods for tracing GMOs have
been initiated.92 Lastly, WHO hopes that “this report could form the basis for a future
85
Cartagena Protocol, supra note 82; see Aarti Gupta, Advance Informed Agreement: A Shared Basis
for Governing Trade in Genetically Modified Organisms?, 9 IND. J. GLOBAL LEGAL STUD. 265 (2001).
86
Comisión Nacional de Recursos Fitogenéticos, Frequently Asked Questions About the Cartagena
Protocol on Biosafety, http://www.conarefi.ucr.ac.cr/Bioseguridad1.htm (last visited May 13, 2006).
87
Cartagena Protocol art. 11, para. 8.
88
See Cartagena Protocol art. 20, para. 1. The Biosafety Clearing House is located at http://bch.biodiv.
org/. For a general discussion of the Cartagena Protocol, see David J. Schnier, Genetically Modified Organisms & the Cartagena Protocol, 12 FORDHAM ENVTL. L.J. 377 (2001).
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WHO STUDY, supra note 14, at 19-20.
90
Under the Cartagena Protocol, a living modified organism (LMO) is defined as “any living organism
that possesses a novel combination of genetic material obtained through the use of modern biotechnology”
and living organism means “any biological entity capable of transferring or replicating genetic material,
including sterile organisms, viruses and viroids.” Cartagena Protocol art. 3(g)-(h).
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WHO STUDY, supra note 14, at 19-20.
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Id. at 23 (citing European Network of GMO Laboratories (2002), available at http://engl.jrc.it/).
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initiative towards more systematic, coordinated, multi-organizational and international
evaluation of certain GM foods.”93
Sharing this initiative, the Organization for Economic Cooperation and Development
(OECD) established the Internal Coordination Group on Biotechnology in 1993 to aid
international coordination in the areas of agriculture, technology, and trade. The OECD
BioTrack provides a clearinghouse of information on biotechnology products and field
trials, as well as Consensus Documents for the Work on Harmonisation of Regulatory
Oversight in Biotechnology.94 This OECD effort seeks to promote international harmonization in the safety assessment and regulation of biotechnology food products,
including conforming food labeling practices, which otherwise would have a potential
to impede international trade in food products as nontariff trade barriers.95
With its precautionary approach, the European Union (EU) has taken a relatively proactive role in enacting strict legislation to control the spread of GMOs. Most significantly, the
EU introduced a new Directive, 2001/18/EC,96 regulating and restricting the distribution
of GMOs and foods containing GM ingredients. The Directive recognizes that
[l]iving organisms, whether released into the environment in large or small
amounts for experimental purposes or as commercial products, may reproduce in the environment and cross national frontiers thereby affecting other
Member States. The effects of such releases on the environment may be irreversible.97
As a result, the Directive mandates that “[t]he protection of human health and the environment requires that due attention be given to controlling risks from the deliberate
release into the environment of [GMOs].”98 Directive 2001/18/EC provides a notification
procedure before a GM product is placed on the market, a period of public comment,
an assessment report, and principles for environmental risk assessment. Following a
“step-by-step” principle, the scale of release is increased gradually only with proper
evaluation at each step, providing first that
[n]o GMOs, as or in products, intended for deliberate release are to be considered for placing on the market without first having been subjected to satisfactory
field testing at the research and development stage in ecosystems which could
be affected by their use.99
The Directive also sets forth specific provisions for labeling and packaging, including
a requirement that the words “this product contains genetically modified organisms”
shall appear either on a label or in an accompanying document.100 For products where
93

WHO, Questions on GM Foods, supra note 4, at Q20.
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96
Council Directive 2001/18/EC, 2001 O.J. (L106), available at http://binas.unido.org/binas/regs.php;
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unavoidable traces of authorized GMOS cannot be excluded, minimum threshold levels for the labeling requirement shall be established.101 Postmarket monitoring by the
industry is required, as well as notifying the authorities of new information and taking
immediate measures necessary to protect human health and the environment.102
Extending beyond the previous Directive 90/220/EC,103 the new Directive allows a
temporary ban of GM products if evidence can be provided exposing risks to human
health or the environment.104 The moratorium has been a source of friction between
the United States and the EU, costing the United States an estimated $200 million in
corn exports.105 The United States has filed a complaint with the WTO challenging the
ban, on the grounds that it is an impediment to trade.106 The ban followed an earlier
action when, in November 2002, the EU approved enhanced traceability and labeling
requirements for biotechnology food and feed.107 The U.S. government previously had
delivered a demarche to the EU in September 2002 outlining U.S. concerns about the
then-pending (traceability and labeling) regulations and their likely adverse impact on
U.S. bulk shipments.108
In response to a series of food safety alarms, the EU, in May 2003, created the
European Food Safety Authority (EFSA) to serve as a “food safety watchdog.”109 The
role of the EFSA differs from its U.S. counterpart in that the EFSA deals only with
101
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the science of risk assessment (determining what risks exist), while FDA also handles
the policy decisions involved in risk management (determining what to do about those
risks and whether they are considered acceptable). The European Parliament wanted an
organization that gave “genuinely objective, independent and public advice,” leaving
the policy judgments to the European Commission.110 Thus, the EFSA will not have a
role in trade disputes before the WTO, but instead hopes to “help bring American and
European scientists together at an early stage in the hope of reducing the political impact
of such differences” because “food safety does not respect boundaries.”111 Another goal
is to instill “a much clearer degree of scientific input into the risk management measures
adopted by the EU” by taking care not to avoid difficult scientific issues of risk assessment for fear of unpopularity.112 At the same time, in light of the European sensitivity
to food issues and past food scares, the EFSA seeks to achieve more transparency and
restore public confidence.
To this end, the Executive Director of the EFSA, Geoffrey Podger, has taken a position in favor of the labeling approach. He explains that when GM products were clearly
labeled in the United Kingdom, many people bought them and initially gave GMOs a
degree of acceptability, “until commodity crops starting arriving from North America
in which GMO and non–GMO varieties could not be differentiated.”113 The European
opposition to GMOs did not come about because the science had changed, but rather it
was based on ethical grounds as a reaction to being denied a choice. As a consequence,
Dr. Podger believes that the solution to regaining the support of the European public
is through labeling:
The great advantage of labeling is that it provides a choice. And while the people
who insist on choice may be quite a small part of the population, they are very
vociferous and they are often in positions of power and prominence.114
Dr. Podger sees potential for the market for GMOs to open if these products have obvious advantages for consumers even in the face of some risk.115 Public perceptions,
he notes, are open to change with new information, as long as the regulatory process
is transparent and gives people all available information on the science. “Equally, of
course, we are always open to new scientific evidence and to improving the regulatory
process if necessary.”116
All GM products seeking to enter the EU market as food or feed must undergo an
extensive authorization procedure, including a scientific safety assessment by the EFSA.
As of 2000, twenty-two nations, including Great Britain, France, Australia, Japan, South
Korea, and Mexico, in addition to the EU, had passed regulations that require GM food
labeling.117 Thus, the EU and the international community continue to pursue an aggressive policy of caution in the regulation of bioengineered foods and food products.118
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IV. A LOOK AT EXISTING U.S. LAW
In contrast to the stringent premarket approval process, mandatory labeling, and
moratoriums in Europe and the international community, the United States has not
developed a regulatory scheme of special safeguards for GMOs because the U.S. government does not recognize biotechnology as posing special risks. As a consequence,
U.S. regulation of biotechnology food products does not differ fundamentally from the
regulation of conventional food products. The United States uses health and safety laws
written prior to the development of modern biotechnology to review genetically engineered products. To date, the United States has not issued any new legislation for these
products.119 Under the 1986 Coordinated Framework for Regulation of Biotechnology,
three agencies primarily share the regulatory oversight responsibility for these products:
USDA and its agencies, which regulate and monitor the use of biotechnology for agriculture, restricting, among other things, the addition of potential plant pests “altered or
produced through genetic engineering”;120 the Environmental Protection Agency (EPA),
which approves new pesticidal and herbicidal substances; and FDA, which has legal
authority with respect to food safety and labeling. Depending on its characteristics, a
product may be subject to review by one or more of these agencies.
The agencies apply existing food safety and environmental protection laws and regulations to GM products and approve their entry into the market based on the characteristics
of the end product rather than on the process by which a product is made. Thus, it is
immaterial that the product originated from genetic engineering.121 Each agency draws
on its own perspective and area of concern. For example, USDA regulates field testing
and examines possible environmental consequences as to plant pests, other organisms,
and weediness characteristics (e.g., the potential to become a weed through ease of seed
dispersal); EPA considers the health effects by assessing allergenicity and digestibility,
the environmental fate such as the potential for cross-pollination, and the effects on
nontarget organisms, particularly whether the introduced pesticidal substance is toxic
to wildlife; and FDA asks the developer voluntarily to address issues of food safety
and allergenicity, examining “whether the introduction of the genetic material into the
plant caused any unexpected effects by analyzing the composition of the food, paying
particular attention to levels of known toxicants and significant nutrients.”122 However,
119
United States Regulatory Agencies Unified Biotechnology Website, Frequently Asked Questions,
http://usbiotechreg.nbii.gov/FAQRecord.asp?qryGUID=2 (last visited May 13, 2006). For a compilation
of the laws currently used to regulate the products of modern biotechnology and the regulations developed
under these statutes (the Plant Protection Act, the Federal Food, Drug, and Cosmetic Act (FDCA), the Federal Insecticide, Fungicide, and Rodenticide Act, and the Toxic Substances Control Act), see United States
Regulatory Agencies Unified Biotechnology Website, U.S. Laws and Regulations, http://usbiotechreg.nbii.
gov/lawsregsguidance.asp (last visited May 13, 2006). See also 1986 Coordinated Framework for Regulation
of Biotechnology, 51 Fed. Reg. 23,302 (June 26, 1986).
120
See, e.g., Introduction of Organisms and Products Altered or Produced Through Genetic Engineering Which are Plant Pests or Which There is Reason to Believe are Plant Pests, 7 C.F.R. § 340 (1997). For
example, USDA’s Biotechnology Regulatory Services, which is a branch of the Animal and Plant Health
Inspection Service, “regulates the field testing, movement, and importation of genetically engineered (GE)
organisms that are known to be, or could be plant pests.” Biotechnology Regulatory Services, Introduction
to Biotechnology Regulatory Services of the Animal & Plant Health Inspection Service, http://www.aphis.
usda.gov/brs/ (last visited May 13, 2006).
121
Stamps, supra note 48, at 5-6.
122
U.S. Dep’t of State, Food Safety: Regulating Plant Agricultural Biology in the United States (Oct.
2000), available at http://usinfo.state.gov/products/pubs/archive/biotech/ (outlines regulatory procedures
from the time a scientist has an idea for a potentially marketable bioengineered plant product to when the
product appears in the local food market).
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“each agency … relies on industry data and rarely completes its own independent
experiments comparing different foods.”123
U.S. regulations do not mandate labeling of GM foods, but instead recommend voluntary labeling of bioengineered foods and request that companies notify FDA of their
intent to market GM foods at least 120 days before launch.124 The inquiry focuses on
whether the GM foods are substantially equivalent to their parent crops.125 If so, only
the general labeling requirements for all foods would apply. For all foods, section 403(i)
of the Federal Food, Drug, and Cosmetic Act (FDCA) requires that “each food bear a
common or usual name or, in the absence of such a name, an appropriately descriptive
term.” In addition, under section 201(n), the label of the food must reveal all material
facts about the food.126 In its 1992 policy statement on foods developed from new plant
varieties including bioengineered foods, FDA emphasized that, while the agency was
not establishing special labeling requirements for bioengineered foods as a class of
foods, this preexisting scheme would apply:
Thus, consumers must be informed, by appropriate labeling, if a food derived
from a new plant variety differs from its traditional counterpart such that the
common or usual name no longer applies to the new food, or if a safety or
usage issue exists to which consumers must be alerted.127
FDA offers as an example a tomato that has had a peanut protein introduced into it. If
“there is insufficient information to demonstrate that the introduced protein could not
cause an allergic reaction in a susceptible population,” a warning on the label “would
be required to alert consumers who are allergic to peanuts.”128 This information would
be “a material fact” whose omission may make the label of the tomato misleading under
section 403(a) of the FDCA.129
From FDA’s perspective, biotechnologically-produced products are seen as substantially equivalent to conventional food products because, in the agency’s view, there is no
scientific basis to presuppose that biotech foods are more risky or substantially different
from other food products. FDA states in its regulations that the agency
believes that the new techniques are extensions at the molecular level of
traditional … plant breeding. The agency is not aware of any information
123

CRS REPORT, supra note 24.
Ahmed, supra note 12, at 215. See, e.g., Premarket Notice Concerning Bioengineered Foods, 21
C.F.R. Parts 192 and 592 (2001), available at http://www.cfsan.fda.gov/~lrd/fr010118.html.
125
There is no definition provided in the regulations for substantial equivalence and no clear and
universal guidelines stipulating what to test and how similar the items in question should be. It has been
said that the amount of comparative data required to establish substantial equivalence involved a somewhat
subjective judgment. ROYAL SOCIETY UPDATE, supra note 18. As a result, this controversial concept has been
disfavored in Europe where the capability to classify a novel food as being substantially equivalent no longer
justifies a lack of safety assessments.
126
21 U.S.C. § 343(i); id. § 343(a); id. § 321(n) (2005); see also Letter from Catalina Ferre-Hockensmith,
Dep’t of Health and Human Servs. (HHS), Div. of Standards and Labeling Regulations, to Vircher B. Floyd
(Sept. 17, 2002), available at http://www.fda.gov/ohrms/DOCKETS/dailys/02/Sep02/092502/8002a5c7.
pdf.
127
Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. 22,984, 22,991 (May
29, 1992).
128
Id. For critiques of this regime, see, for example, Lara Beth Winn, Special Labeling Requirements
for Genetically Engineered Food: How Sound Are the Analytical Frameworks Used by the FDA and Food
Producers?, 54 FOOD & DRUG L.J. 667 (1999); Carl R. Galant, Comment, Labeling Limbo: Why Genetically
Modified Foods Continue to Duck Mandatory Disclosure, 42 HOUS. L. REV. 125 (2005).
129
21 U.S.C. § 321(n), cited in Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed.
Reg. at 22,991.
124
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showing that foods derived by these new methods differ from other foods in
any meaningful or uniform way, or that, as a class, foods developed by the
new techniques present any different or greater safety concern than foods
developed by traditional plant breeding. For this reason, the agency does not
believe that the method of development of a new plant variety (including the
use of new techniques including [rDNA] techniques) is normally material
information … and would not usually be required to be disclosed in the labeling for the food.130
Accordingly, if GM soy contains the same nutritional and dietary content as its predecessor, FDA does not require that it be labeled as a biotechnologically altered food.
This policy was reaffirmed by FDA in 2001 in its Draft Guidance for Industry allowing
voluntary labeling indicating whether foods have or have not been developed using
bioengineering.131
FDA’s treatment of GM foods contrasts with its handling of the irradiation of food,
which was a food processing technology considered by the agency to be a “material fact”
necessary to disclose to consumers through labeling. FDA approved the use of ionizing
radiation on various foods under specific conditions.132 Although FDA determined that
“there is no concern about the safety of such treatment,” the agency concluded that labeling of irradiated foods was necessary because such processing is a material fact that
must be disclosed to the consumer to prevent deception. FDA determined that irradiation
is a form of processing that can produce significant changes in certain characteristics
of a food, such as the organoleptic (e.g., taste, smell, texture) or holding properties, in
a manner that is not obvious to the consumer in the absence of labeling. That is, in the
absence of labeling indicating that the food has been irradiated, the implied representation to consumers is that the food has not been processed.133
FDA thus required that the label and labeling of retail packages or displays of foods
treated with ionizing radiation include both the radura logo (the international symbol
that indicates radiation treatment) and a disclosure statement (either “Treated with
radiation” or “Treated by irradiation”‘) in addition to information required by other
regulations.134 In mandating a disclosure on all irradiated foods, FDA was cognizant of
widespread consumer concerns about food irradiation. According to the agency, “the
large number of consumer comments requesting retail labeling attest to the significance
placed on such information by consumers.”135
Supporters of GM food labeling point to FDA’s irradiated foods analysis as being
applicable as well to GM foods, reasoning that “the absence of an affirmative statement
that a food had been genetically modified would be viewed as an implied representation
to consumers that it has been grown by traditional means.”136 In Alliance for Bio-Integ130

Statement of Policy: Foods Derived From New Plant Varieties, 57 Fed. Reg. at 22,991.
CFSAN, FDA, Draft Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or
Have Not Been Developed Using Bioengineering (Jan. 2001) [hereinafter FDA, Draft Guidance on Voluntary
Labeling], available at http://vm.cfsan.fda.gov/~dms/biolabgu.html.
132
Irradiation in the Production, Processing and Handling of Food, 21 C.F.R. § 179.26 (2003).
133
Irradiation in the Production, Processing, and Handling of Food, 21 C.F.R. Part 179, 64 Fed. Reg.
7834 (Feb. 17, 1999), citing Irradiation in the Production, Processing, and Handling of Food, Final Rule, 51
Fed. Reg. 13,376 (Apr. 18, 1986); Irradiation in the Production, Processing, and Handling of Food; Final
Rule, 53 Fed. Reg. 12, 757 (Apr. 18, 1988).
134
21 C.F.R. § 179.26(c)(1), (2).
135
51 Fed. Reg. at 13,388.
136
Emily Marden, Risk and Regulation: U.S. Regulatory Policy on Genetically Modified Food and
Agriculture, 44 B.C.L. REV. 733, 763 (2003); see also Frederick Degnan, Food Labeling and the Right-toKnow, 52 FOOD & DRUG L.J. 49 (1997).
131
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rity v. Shalala,137 a group of concerned citizens sued FDA claiming that the agency’s
refusal to require labeling and safety testing raises health and environmental concerns
and makes it difficult to comply with religious dietary laws. The suit identified thirtysix genetically modified foods being consumed daily without the knowledge of U.S.
consumers. Seeking to apply the food-processing reasoning used for irradiated foods,
the plaintiffs demanded that FDA institute mandatory labeling of GM foods on the
grounds that genetic alteration made material changes (i.e., safety, allergenicity risks)
to foods. The plaintiffs took the position that the process of being genetically modified
was itself a material fact. The court rejected both of these arguments, however, and
affirmed FDA’s position.138
In November 2004, FDA proposed a Draft Guidance for Industry for New Plant
Varieties Intended for Food Use “to address the possibility that material from a new
plant variety intended for food use might inadvertently enter the food supply before its
sponsor has fully consulted with the [FDA].”139 This draft guidance provides a scientific
framework in which to evaluate the food safety of new nonpesticidal proteins produced
in bioengineered plants,140 and encourages developers to submit to FDA their evaluation
of the food safety of their new protein. FDA recognized the possibility that
[s]cientific advances are expected to accelerate over the next decade, leading
to the development and commercialization of a greater number and diversity
of bioengineered crops. As the number and diversity of field tests for bioengineered plants increase, the likelihood that cross-pollination due to pollen drift
from field tests to commercial fields and commingling of seeds produced during
field tests with commercial seeds or grain may also increase.141
FDA recommends that sponsors and developers of new plant varieties intended for food
use “consult with FDA about their evaluation of the food safety of any new proteins
produced in these plants prior to the stage of development where the new proteins might
inadvertently enter the food supply.”142 The agency made it clear, however, that any concern related to such material entering the food supply would be limited to the possibility
that the new protein could cause an allergic reaction in susceptible individuals or could
be a toxin in people or animals.143 Additionally, FDA stressed that this draft guidance
137

Alliance for Bio-Integrity v. Shalala, 116 F. Supp. 2d 166, 178 (D.D.C. 2000).
Id.
139
FDA, FDA Talk Paper, FDA Proposes Draft Guidance for Industry for New Plant Varieties Intended
for Food Use (Nov. 19, 2004), available at http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01327.
html; Draft Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New NonPesticidal Proteins Produced by New Plant Varieties Intended for Food Use, 69 Fed. Reg. 68,381 (Nov. 24,
2004); see also HHS, HHS News, FDA to Strengthen Pre-Market Review of Bioengineered Foods (May 3,
2000), available at http://www.cfsan.fda.gov/~lrd/hhbioen2.html (announcing FDA’s “plans to draft labeling
guidance to assist manufacturers who wish to voluntarily label their foods being made with or without the
use of bioengineered ingredients”).
140
This guidance concerns developers of new plant varieties that are intended for food use, describing
procedures for the early food safety evaluation of such new nonpesticidal proteins. FDA notes that, because
EPA is responsible for assessing the safety of pesticides including plant-incorporated protectants, those
proteins are not subject to FDA review or this guidance. See FDA, Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties
Intended for Food Use (2004) [hereinafter FDA, Guidance for Industry, Recommendations for Early Food
Safety Evaluation], available at http://www.cfsan.fda.gov/~dms/bioprgui.html.
141
FDA Talk Paper, supra note 139.
142
FDA, Guidance for Industry, Recommendations for Early Food Safety Evaluation, supra note 140.
143
Draft Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New NonPesticidal Proteins Produced by New Plant Varieties Intended for Food Use, 69 Fed. Reg. at 68,382.
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does not establish legally enforceable responsibilities, but “describe[s] the agency’s
current thinking on a topic and should be viewed only as recommendations … .”144
Note that the U.S. approach differs greatly from the international approach embodied
by the Codex principles and Cartagena Protocol, most significantly by not adopting
the precautionary principle that would require premarket approval conditioned upon
a case-by-case risk assessment to consider the intended and unintended effects of the
GM product before its release.145 In promulgating its regulatory scheme, FDA appears
to have given little weight to the scientific uncertainty and risks recognized by its EU
counterparts as inherent in GMOs.146 FDA’s regulations go no farther than recommendations to the industry of communication with the agency and, unlike the EU and
international regulations, do not require disclosure of GM processes to the consumer.
The absence of mandatory labeling and monitoring, as well as a premarket approval
process, stands in stark contrast to the approach overseas.
Efforts to strengthen the U.S. government’s control of GM foods through legislation
have been unsuccessful thus far. In May 2002, Representative Dennis J. Kucinich (D-OH)
introduced H.R. 4814, the Genetically Engineered Food Right to Know Act, a bill that
would require labeling of biotechnology food products.147 The purpose of the bill was
“[t]o amend the Federal Food, Drug, and Cosmetic Act, the Federal Meat Inspection
Act, and the Poultry Products Inspection Act to require that food that contains a genetically engineered material, or that is produced with a genetically engineered material,
be labeled accordingly.”148 Although H.R. 4814 gained thirty-eight cosponsors, the bill
died in a subcommittee.149
H.R. 4814 was one of five bills introduced by Rep. Kucinich that sought to expand
the regulation of agricultural biotechnology. H.R. 4812, the Genetically Engineered
Crop and Animal Farmer Protection Act, would “provide additional protections for
farmers and ranchers that may be harmed economically by genetically engineered
seeds, plants, or animals,” establishing a Farmer’s Bill of Rights “to ensure fairness for
farmers and ranchers in their dealings with biotechnology companies that sell genetically engineered seeds, plants, or animals.”150 Among these protections, the bill would
require disclosure by the biotechnology companies of the legal and environmental
Based on [the] EPA’s finding that the genetically engineered proteins in Bt 10 are safe, the extremely
low levels of Bt 10 corn in the food and feed supply, and the fact that corn does not contain any
significant natural toxins or allergens, [the] FDA has concluded that the presence of Bt 10 corn
in the food and feed supply poses no safety concerns.
CFSAN, FDA, U.S. Food and Drug Administration’s Statement on Bt 10 (Apr. 27, 2005), available at
http://www.cfsan.fda.gov/~lrd/biobt10.html.
144
FDA, Guidance for Industry, Recommendations for Early Food Safety Evaluation, supra note
140.
145
In fact, in discussions of the Codex, the United States has consistently battled with Europeans over
their incorporation of the precautionary principle into regulation of GM technology. See, e.g., Marden, supra
note 136, at 786 (citing FDA Public Meeting on the Codex Ad Hoc Intergovernmental Task Force on Food
Derived from Biotechnology (Dec. 15, 1999)).
146
The United States has vigorously resisted “any efforts to regulate GM technology based on the development process, or on grounds of potential health or environmental risks,” opposing the European Commission
and others in the drafting of the Convention on Biological Diversity, which “permit[ted] non-scientifically
based measures to justify exclusion of GM products from entry into a country.” Id. at 786-87.
147
Genetically Engineered Food Right to Know Act, H.R. 4814, 107th Cong. (2002).
148
Id.
149
H.R. 4814 was referred to the House Subcommittee on Farm Commodities and Risk Management
on June 4, 2002. Id.; see also Pew Initiative on Food and Biotechnology, Factsheet, United States H.R. 4814
(May 2005), http://pewagbiotech.org/resources/factsheets/legislation/bill.php?LegislationID=167.
150
Genetically Engineered Crop and Animal Farmer Protection Act of 2002, H.R. 4812, 107th Cong.
(2002).
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risks that the use of the genetically engineered seeds, plants, or animals may pose to
the purchaser; prevent noncompetitive practices involving technology fees; preclude
the biotechnology company from limiting liability for harm that may result from the
release of genetically engineered material into the environment; and prohibit the sale of
certain nonfertile plant seeds (a seed that is genetically engineered to produce a plant
whose seeds are not capable of reproduction).
H.R. 4813, the Genetically Engineered Food Safety Act, would “amend the Federal
Food, Drug, and Cosmetic Act with respect to the safety” of biotech foods.151 This bill
explicitly recognized that “genetic engineering is an artificial gene transfer process
wholly different from traditional breeding” and considered adding new genes into a food
as comparable to adding a food additive, thus requiring an analysis of safety factors:
Given the consensus among the scientific community that genetic engineering can potentially introduce hazards, such as allergens or toxins, genetically
engineered foods need to be evaluated on a case-by-case basis and cannot be
presumed to be generally recognized as safe.152
H.R. 4813 would require that all GMOs be determined safe for human consumption prior
to release in the market, and would give FDA the right to impose independent testing
and to seek input from the National Academy’s Institute of Medicine. Further, the bill
would authorize citizen suits for genetic food additives in the event of noncompliance
with these provisions.153
H.R. 4815, the Real Solutions to World Hunger Act, would restrict genetically engineered exports to GMOs approved in the United States and by the importing nation.154
By its terms, the bill asserted that “[t]he need for mandatory labeling, safety testing, and
environmental reviews of genetically engineered foods do not constitute obstacles to the
cessation of world hunger.”155 The stated purpose was “[t]o ensure that efforts to address
world hunger through the use of [biotech] animals and crops actually help developing
countries and people, while protecting human health and the environment … .”156 H.R.
4815 would support funding for international research that promotes the development of
sustainable agriculture techniques with minimum artificial inputs to meet the food and
fiber needs of developing countries.
Finally, H.R. 4816, the Genetically Engineered Organism Liability Act, would hold
biotechnology companies liable to any party for injuries caused by the release of a
genetically engineered organism into the environment.157 The list of potential injuries
included crop failures suffered by farmers, cross pollination of neighboring farms, and
increased insect resistance, as well as health and environmental impacts on consumers.158
All of these bills were referred to subcommittees with no further action.
Likewise, in the U.S. Senate, Senator Richard Durbin (D-IL) in October 2002 introduced S. 3095, the Genetically Engineered Foods Act (GEFA), a bill “to amend the
Federal Food, Drug, and Cosmetic Act to require premarket consultation and approval
with respect to genetically engineered foods, and for other purposes.”159 This legisla151
152
153
154
155
156
157
158
159

Genetically Engineered Food Safety Act of 2002, H.R. 4813, 107th Cong. (2002).
Id.
Id.
Real Solutions to World Hunger Act of 2002, H.R. 4815, 107th Cong. (2002).
Id.
Id.
Genetically Engineered Organism Liability Act of 2002, H.R. 4816, 107th Cong. (2002).
Id.
Genetically Engineered Foods Act, S. 3095, 107th Cong. (2002).
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tion would require FDA to review and approve all genetically engineered foods prior
to introduction into interstate commerce. It would authorize approval exemptions for
a food category deemed not to be a food safety risk and would provide for trade secret
protection. Specifically, the GEFA would direct the Secretary of Health and Human Services (HHS) to establish 1) a program to test for the presence of genetically engineered
ingredients in food from all stages of agricultural production to retail distribution and
2) a genetically engineered food registry that contains the regulatory status of all such
approved foods. S. 3095 also applied provisions respecting adulterated drugs and devices
to genetically engineered animals; set forth application criteria, including provisions for
protection of trade secrets and environmental assessments; and incorporated prohibitions
against unlawful use of trade secret information and adulterated food. There apparently
was no action on this bill, as it died in committee.160
Congress does not appear to be supporting initiatives to address food safety concerns
and to tighten the regulatory process for bioengineered food in the United States. In
the 108th Congress (2003-2004), thirteen bills and two resolutions specifically addressing agricultural biotechnology were introduced. Of those, only two nonbinding
resolutions—supporting the Administration’s efforts to bring a complaint against the
European Union for its restrictions on GM crops—passed (H.R. Res. 252 and S. Res.
154).161 The stated purpose of these resolutions was to express the support of the House
of Representatives and the Senate for the United States “in its efforts within the World
Trade Organization (WTO) to end the European Union’s protectionist and discriminatory trade practices of the past five years regarding agriculture biotechnology.”162 Each
resolution “supports and applauds the efforts of the Administration on behalf of the
Nation’s farmers, challenging the long-standing, unwarranted moratorium imposed by
the European Union on the approval of agriculture biotechnology products and encourages the President to continue to press this issue … .”163
With the U.S. Congress continuing to take relatively little action on biotechnologyfocused legislation to alter the way GM foods are regulated,164 state legislatures have
come forward as the main venue for issues pertaining to agricultural biotechnology.165
In the 2003-2004 legislative session, 170 pieces of legislation (156 bills and fourteen
resolutions) were introduced in thirty-five different states, representing a seven percent
increase over the amount of legislation introduced in thirty-nine state legislatures in
2001-2002.166 This increase indicates a growing trend that agricultural biotechnology
issues generate a high level of interest among state legislators and their constituents.
The state legislation can be classified into several broad categories: regulating biotech
crops and animals, labeling, liability and agricultural contracts, studies or task forces,
supporting the technology, implementing moratoria, or criminalizing crop destruction.
Of the thirty-seven pieces of legislation that passed in 2003-2004, a majority (21) fell
160
Id. On the day it was introduced in the Senate, it was read twice and referred to the Committee on
Agriculture, Nutrition, and Forestry.
161
H.R. Res. 252, 108th Cong. (2003) (introduced by Rep. Roy Blunt, R-MO); S. Res. 154, 108th
Cong. (2003) (introduced by Sen. Jim Talent, R-MO); see also Pew Initiatives on Food and Biotechnology,
Factsheet, State Legislative and Local Activities Related to Agricultural Biotechnology Continue to Grow in
2003-2004 (May 2005), http://pewagbiotech.org/resources/factsheets/legislation/factsheet.php [hereinafter
PEW Legislative Activities].
162
H.R. Res. 252.
163
S. Res. 154, 108th Cong. (2003).
164
A review of the current legislative session (109th Congress, 2005-2006) finds no pending bills or
resolutions involving GMOs or food biotechnology. See The Library of Congress: THOMAS, http://thomas.
loc.gov/ (last visited May 13, 2006).
165
PEW Legislative Activities, supra note 161.
166
Id.
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into the category of “supporting biotechnology.” Nationally, there was a large increase
in the number of bills introduced that support biotechnology, particularly as a tool for
economic development. In 2004, two states passed legislation that would “assert state
preeminence over agricultural biotechnology and prevent local initiatives from countering state authorities.”167
One trend in 2003-2004 was the increase in legislation addressing “novel” applications of agricultural biotechnology, beyond the corn, cotton, and soybeans modified
for herbicide or insect resistance that have proliferated in the United States: “The next
generation of agricultural biotechnology products is likely to include new food or feed
crops (possibly alfalfa, wheat, coffee, or rice); transgenic fish or other aquatic organisms; transgenic crops and livestock genetically modified to produce human therapeutics
or industrial compounds; and other genetically modified animals.”168 Regional issues
appear to dominate the kinds of legislation introduced by state lawmakers. “But some
state legislation has also addressed labeling and the safety of new products such as
transgenic fish—areas much more commonly handled by federal agencies.”169 State
legislatures across the nation passed seven bills regulating biotech crops or animals,170
three bills addressing labeling,171 one bill on the subject of liability and agricultural
contracts,172 four pieces of legislation in the study/task force category,173 and one bill
imposing a moratorium.174 These developments potentially raise issues of a constitutional dimension, such as preemption and the Commerce Clause.175 In the absence of
a comprehensive system of federal legislation, these state and local restrictions could
result in “a patchwork of inconsistent regulatory requirements … .”176

V. A MODEL OF CAUTION: LABELING AND MONITORING
Despite the benefits of biotechnology, the safety issues from unintended and unknown
risks and scientific uncertainty necessitate a more effective approach to risk assessment
in the United States. Without transparency as to the presence of GM products in food,
informed choice cannot be realized. This lack of information also impedes the development of biotechnology in the long run. A report by the Atlantic Council of the United
167

Id.
Id.
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Id.
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See Arizona HB2615, Michigan SB226, Michigan SB227, Michigan SB228, Michigan SB229,
Pennsylvania HB2387, and South Dakota HB1237, cited in PEW Legislative Activities, supra note 161.
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See Vermont HB 777, Pub. Act No. 97 (2004) (requires all GM seed to be labeled with information
describing the trait; requirements for safe handling, storage, transport, and use; and information about the
manufacturer; all manufacturers of GM seed are required to report to the secretary the quantities sold annually); Minnesota SF 2843 (passed Mar. 15, 2004, but presumed dead in Committee) (provides guidelines for
voluntary labeling of dairy products produced from cows not treated w rBGH (rBST) and mandates that dairy
products derived from cows that have been treated with rBGH be labeled as such); Maine HP 1149 (2003)
(imposes a civil violation for any manufacturer, distributor, processor, wholesaler or retailer who falsely labels
any product such as commercial feed as made without genetic engineering or bioengineering).
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See Illinois HB 264, cited in PEW Legislative Activities, supra note 161.
173
See Hawaii SB 837, Illinois SR 89, Montana SJ 8, and New Mexico SMR 62, cited in PEW Legislative Activities, supra note 161.
174
A moratorium on transgenic fish passed in California. California SB 245, ch. 871, Statutes of 2003
(2003), cited in PEW Legislative Activities, supra note 161.
175
See Eric Lasker, Federal Preemption and State Anti-“GM” Food Laws, 20 LEGAL BACKGROUNDER
1 (2005) (conflict between favorable federal law and restrictive state legislative laws may raise preemption
issues); Eric Lasker, FDA Position on Federal Preemption Consistent with Law & Public Health, 20 LEGAL
BACKGROUNDER 1 (2005) (FDA asserting in court proceedings that the agency’s labeling of FDA-regulated
products, including prescription drugs, should be given preemptive effect over state law).
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States found that “[c]onsumer confidence is the most important determinant of any future
market [in] … biotechnology.”177 The Council concluded that a credible scientific risk
assessment process is essential, and that some form of labeling and traceability may be
useful in providing consumers with information and choice.178
With regard to GMOs, the most prevalent view is the demand for information and for
choice. According to recent polls, 94.6% of Europeans want the right to choose whether
or not they eat food that has been genetically modified.179 Other studies in Japan and
Europe indicated a decline of confidence in the biotechnology product.180 Bioengineered
food will face increasing resistance from consumers worldwide until transparent and
reliable information, as well as evidence of the potential risks, can be provided.181
A similar survey in the United States showed that almost two-thirds of the respondents were very concerned or somewhat concerned about the food safety problem of
GM products. 182Among the U.S. consumers recently surveyed, there appears to be little
awareness concerning the genetic modification of agricultural and food products.183 Only
two in five Americans (forty-one percent) say that they realize that genetically modified
food products currently are for sale in supermarkets.184 Even so, over seventy-five percent of Americans stated that the potential danger from genetic modification is so great
that strict regulations are necessary; yet sixty-three percent believe that the government
does not have the tools to regulate GMOs properly.185 Nine out of ten Americans said
that GM foods should be labeled as such, although only about half said they actually
would take time to look for foods labeled as not being genetically modified.186 (This last
point should be welcome news for the biotechnology industry, which may be concerned
about the impact of labeling on sales.) In another poll, ninety-three percent of Americans agreed that the federal government should require labels identifying genetically
modified or bioengineered foods. “Such near unanimity in public opinion is rare.”187
Even among American farmers, “90 [percent] … . support labels on biotech products
if they are scientifically different from conventional foods and 61 [%] support labels
on biotech products even if not scientifically different.”188 The increased attention from
177
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the public and erosion of consumer confidence should compel regulators and legislators
to reexamine current policies.
In the past, FDA recognized this mandate from the people but rejected mandatory
labeling based on the restraints of the agency’s own regulatory scheme and FDA’s narrow reasoning as to the role of undetermined risks, stating that
[m]ost of the comments that addressed labeling requested mandatory disclosure
of the fact that the food or its ingredients was bioengineered or was produced
from bioengineered food. However, these comments did not provide data or
other information regarding consequences to consumers from eating the foods
or any other basis for FDA to find under section 201(n) of the act that such
a disclosure was a material fact. Many of the comments expressed concern
about possible long term consequences from consuming bioengineered foods,
but they did not contend that any of the bioengineered foods already on the
market have adverse health effects. The comments were mainly expressions
of concern about the unknown.189
In reviewing the more than 50,000 written comments about its policy, FDA did acknowledge “there was general agreement that providing more information to consumers about
bioengineered foods would be useful.”190 FDA’s position rejecting mandatory labeling
based mainly on “concerns about the unknown” contrasts directly with the precautionary principle embodied in the Cartagena Protocol, which does not allow the “[l]ack of
certainty due to insufficient relevant scientific information and knowledge” to prevent
restrictions on imports to avoid these “potential adverse effects.”191 The ultimate question is who bears the burden of proving that these substances are not hazardous—the
companies before approval or the consumers who fear the potential hazards. Science
is fallible—who do we want to bear the risk of as-yet undetected hazards? If the U.S.
government does not require a rigorous pre-approval process as do the Europeans, at
the very least it should require the food to be labeled so that consumers can individually make this choice. Moreover, there can then be some chance of removal from the
market if, through the development of scientific assessment techniques and long-term
studies, problems are discovered later.
Countries that have introduced mandatory labeling legislation for GM foods have
done so to give their consumers a choice in selecting foods according to their comfort
level.192 Transparency can be ensured only by requiring labeling and traceability of
food products derived from GM plants at all stages of production and distribution.193
Realizing the potential of agricultural biotechnology in the United States and worldwide will require activist policy reform rather than a laissez-faire approach. It has been
suggested that countries tailor their regulations so as to minimize harm to trade while
also responding to consumer concerns.194 Indeed, FDA initially began investigating the
189
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use of voluntary labeling for GM products to ease tensions with trading partners such
as the European Union.195
Industry has begun to respond as well to the perceived risks of biotechnology in
food. Fearful of losing buyers, large food producers have underscored their acceptance
of consumer demands for labeling and have asked suppliers to segregate fields, grain
bins, and storage elevators, with some even paying a premium for non-GM crops.196
Frito-Lay made headlines when, in response to consumer worries, the company told
its suppliers not to use genetically altered corn.197 Additionally, farmers have expressed
concern that markets for unmodified grain could be threatened because crops such as
maize and canola risk contamination by cross-fertilization with windborne pollen.198
In examining the regulatory options, it is important to acknowledge and evaluate the
economic costs; however, mandatory GM labeling may not involve such prohibitive
costs. A study by an agricultural economist at Oregon State University reported that,
for other countries that label GM foods, the total annual costs range from twenty-three
cents per person to about ten dollars per person, depending on the level and complexity of the labeling.199 The analysis of these countries determined that the cost ranged
from twenty-three cents a year for each consumer for labeling only those products
made directly from genetically modified foods, to $3.89 for labeling of products in
which genetically modified substances were used during production or processing. The
estimated costs for the more extensive GM labeling options under consideration in the
United Kingdom, New Zealand, and Australia were calculated as $3 to $10 a year per
person.200 Moreover, the actual cost may be lower to the extent that product segregation,
identity preservation, and labeling already are becoming routine for exporters to foreign
markets where GM labeling is required.201 In addition, there may be reduced costs in the
form of a significantly diminished risk of liability from lawsuits, at least with respect
to potential claims for injuries that may occur due to a failure to warn.202
Mandatory labeling of GMOs generally does incur a higher cost than voluntary
labeling because the entire market must be segregated and labeled even though only
a subset of producers or consumers cares about the attribute. A government’s choice
about whether to require labeling is based in part on what proportion of their citizens
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want information about the technology.203 As demonstrated in the surveys above, the
U.S. consumer has now reached the point where such information is desired by a vast
majority of the citizens and demanded by a vocal portion of these consumers and
farmers.204 The time has come for the U.S. government to be responsive to its citizenry
and restore consumer confidence in the food supply—both domestic and abroad—by
requiring the disclosure of this critical feature.
Such labeling could be either positive labels stating that “This product may contain
GMOs”; or negative labels stating that “This product (or seed) contains no GMOs.”205
In the past, for companies wanting to advertise products as non-GM, FDA has indicated
that it would not allow labels like “GM-free,” “GMO-Free” or “biotech-free.” The agency
reasoned that guaranteeing a product to be free of GM material is virtually impossible
because to establish a threshold “would require methods to test for a wide range of genetic changes at very low levels in a wide variety of foods” and “such methods are not
available at this time”; but stated that the labels could say the food was “not developed
using bioengineering.”206 In determining the requisite labeling, the U.S. government,
particularly FDA, should study the effectiveness of notification of the consumer, the
potential impact on industry, and take into account international standards for uniformity
(such as the OECD effort discussed above) in order to facilitate international trade. If
the labeling requirements conform to a uniform international standard in their wording
and content, the costs for industry in the global marketplace will be reduced.
For these goals to be attained there must be some form of positive labeling indicating the presence or possible presence of GMOs, in order to be an effective notification
mechanism both for consumers in the United States and importers from abroad. Voluntary
negative labeling alone will not be adequate. A mandatory positive labeling requirement
also will target the appropriate segment of the industry. The costs of such labeling thus
will be borne, at least in the first instance, by those in the industry who have benefited
from GM technology. Some of these costs ultimately will be passed on to the consumer,
but surveys show that the U.S. consumer finds this labeling to be important and the
addition of this labeling is a choice supported by the citizenry.
As food companies adapt to changes in the regulatory climate, they will need to
devise marketing strategies that work with labeling policies in promoting the safety
and desirability of their products.207 Thus, the most effective labeling scheme would
include both mandatory labels indicating those products “made with GM ingredients”
or that “may contain genetically modified ingredients,” as a necessary disclosure to
consumers; and voluntary labeling for foods that are “not made with GM processes” or
“not produced through bioengineering,” highlighting this feature as a positive marketing
tool to consumers. Note that as consumer preferences shape market forces, the costs
of these voluntary negative labels will be absorbed by the successful producers (i.e.,
factored in as increased sales). Indeed, this type of labeling already has been sought by
203
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the segments of the industry that would benefit from its marketing impact. FDA supports such labeling as long as it is truthful and not misleading.208
In labeling the presence of GMOs, a minimum threshold level may be determined so
that a reasonably low percentage of accidental GMO presence may be allowed before
invoking the requirement of a mandatory positive label.209 This practical and scientifically feasible approach is reflected in EU Directive 2001/18/EC and differs from the
“GM free” certification disfavored by FDA as misleading. Still, the requirement must
be workable and enforceable through credible scientific assessment and testing.210
In addition to labeling, GM products should be subject to a rigorous system of
pre- and postmarket monitoring. Testing does involve additional costs for the industry,
but such testing, which FDA requires premarket in other areas such as food and color
additives,211 is necessary to protect the public. The National Research Council report
discussed supra proposed postmarket surveillance to identify and monitor unanticipated
compositional changes and health effects of all altered foods, noting that the current
safety assessments only apply to genetically engineered goods before they are put on
the market with a focus on identifying any significant differences in physical characteristics of the plant. The report recommended implementing a safety assessment prior
to and after commercialization, involving federal agencies in the determination, using
standardized sampling methodologies, and improving tracing and tracking methods
when warranted.212
Once monitoring is mandated in the United States, scientists will focus their efforts on the development of appropriate means to detect and track GM foods and their
components. In response to EU regulations, scientists have attempted to assess and
improve reliable and sensitive methods for GMO detection.213 Several of these methods
need further refinement to surmount their limits (e.g., heating and other processes in
food production can degrade DNA and lead to false-positive rates and disappearance
of marker genes).214 As scientific research on the long-term human health and environ208
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mental effects of bioengineered food progresses, the postmarket monitoring of products
containing GMOs will be critical in tracing, in the event that it becomes necessary to
withdraw such products from the market and food chain.
Of significant concern to U.S. producers is “the fact that U.S. farm, grain storage,
and transportation systems are not designed to segregate bulk, untagged, biotechnology
agricultural products, on a large scale and with precision, from conventional varieties.”215
These changes in the storage and transportation structure would place added costs on
the U.S. farm sector. In addition, according to the State Department, the U.S. government “‘does not have the authority to force farmers to market their crop in one channel
or another. Therefore, the U.S. [g]overnment [cannot] certify that certain varieties are
completely absent from export channels.’”216 But if this is true in view of the dangers of
unintended cross-contamination—that biotechnology crops will crossbreed with other
plants resulting in unintended harmful breeds—the consequences for biodiversity are
far more severe than simple economic costs, even if the cost of labeling and segregating
proves to be considerable. If these genetic modifications cannot be monitored effectively,
a more extreme remedy such as a ban may be necessary.

VI. CONCLUSION
The United States should adopt labeling requirements modeled after international
law, choosing the vigilant approach regarding the use of GMOs in food in light of the
unknown scientific effects and a number of initial harmful results. The point is not that
all scientists agree, as would never occur, but that there are enough negative implications with regard to GMOs to question the relatively laissez-faire U.S. policy. When
faced with significant scientific debate, the U.S. government should err on the side of
caution, particularly when it involves something as critical as the U.S. food supply.
That is the position Congress and FDA have taken in the past with food and color additives and irradiated food. This apparent inconsistency raises the query, why are these
governmental units treating this type of food product differently?
In view of the scientific uncertainty, risk assessment is essential to determining who
should bear the risk while identifying and quantifying those risks through responsible
and appropriate scientific methods.217 Particularly when considering the nonquantifiable
risks, public safety and health considerations should prevail.
A comprehensive system of pre- and postmarket monitoring, enhanced testing, and
appropriate labeling would realize benefits for all stakeholders. Implementing these
measures would aid consumers by increasing the likelihood of informed decisionmaking,
industry by increasing the confidence of consumers, and environmentalists by developing safety provisions without the need for moratoriums. In addition, by establishing
standards more consistent with the international scientific community for risk assessment and labeling, industry may benefit from more streamlined and timely approval for
marketing in the United States with fewer obstacles from abroad.218
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It is important to recognize that, inasmuch as these issues reflect cultural differences
in levels of risk aversion with respect to food and food products, they also involve
international trade policy and economic concerns beyond matters of science.219 As a
matter of international trade, the biotechnology industry must “accept the challenge of
developing and regulating products that take into account regional diverse needs and
concerns of consumers and specificities of the environment.”220
The United States must address these critical environmental concerns and consumer
demands through legislation and regulation to improve risk management. Only then
will it be possible for the biotechnology industry to introduce GMOs into worldwide
markets without significant opposition.221 If neither the U.S. government nor industry
moves forward to attend to these risks in a meaningful way, increased public awareness and pressure from abroad may further impede international trade and, eventually,
necessitate a ban of GMOs in the U.S. food supply. Thus, for the sake of the biotechnology industry, as well as the consumer, adopting this more cautious approach would
offer GMOs the most viability in the long run to attain some of the initial promise and
secure a future in food.
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